Advertisement

Vascular Anomalies

  • Austin N. DeHartEmail author
  • Joana M. Mack
  • P. Spencer Lewis
  • Shelley E. Crary
  • Gresham T. Richter
Chapter

Abstract

Vascular anomalies are physical manifestations of disrupted vascular development in the form of uncontrolled cellular growth or vessel communication and expansion. They may arise as congenital or de novo lesions to cause aesthetic and/or functional problems. The International Society for the Study of Vascular Anomalies (ISSVA) categorizes vascular anomalies between vascular tumors and vascular malformations (VM) (Wassef et al. Pediatrics 136(1):e203–14, 2015). Vascular malformations are further subdivided by blood vessel type and as high-flow lesions, when an arterial component is present, or low-flow lesions which contain capillary, venous, or lymphatic components. These may be simple, comprised of only one vessel type, or combined, with multiple types of vessels involved.

Keywords

Vascular anomalies Infantile hemangiomas Arterial venous malformations Capillary malformations Port-wine stains Lymphatic malformations 

References

  1. 1.
    Wassef M, Blei F, Adams D, et al. Vascular anomalies classification: recommendations from the International Society for the Study of Vascular Anomalies. Pediatrics. 2015;136(1):e203–14.  https://doi.org/10.1542/peds.2014-3673.CrossRefPubMedGoogle Scholar
  2. 2.
    Finn MC, Glowacki J, Mulliken JB. Congenital vascular lesions: clinical application of a new classification. J Pediatr Surg. 1983;18(6):894–900.CrossRefGoogle Scholar
  3. 3.
    Darrow DH, Greene AK, Mancini AJ, Nopper AJ. Section on dermatology, section on otolaryngology–head and neck surgery, and section on plastic surgery SOOANS and SOPS. Diagnosis and management of infantile hemangioma. Pediatrics. 2015;136(4):e1060–104.  https://doi.org/10.1542/peds.2015-2485.CrossRefPubMedGoogle Scholar
  4. 4.
    Dickison P, Christou E, Wargon O. A prospective study of infantile hemangiomas with a focus on incidence and risk factors. Pediatr Dermatol. 2011;28(6):663–9.  https://doi.org/10.1111/j.1525-1470.2011.01568.x.CrossRefPubMedGoogle Scholar
  5. 5.
    North PE, Waner M, Mizeracki A, Mihm MC. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol. 2000;31(1):11–22.CrossRefGoogle Scholar
  6. 6.
    Horii KA, Drolet BA, Frieden IJ, et al. Prospective study of the frequency of hepatic hemangiomas in infants with multiple cutaneous infantile hemangiomas. Pediatr Dermatol. 2011;28(3):245–53.  https://doi.org/10.1111/j.1525-1470.2011.01420.x.CrossRefPubMedGoogle Scholar
  7. 7.
    Orlow SJ, Isakoff MS, Blei F. Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a “beard” distribution. J Pediatr. 1997;131(4):643–6.CrossRefGoogle Scholar
  8. 8.
    Rosenberg TL, Suen JY, Richter GT. Arteriovenous malformations of the head and neck. Otolaryngol Clin N Am. 2018;51(1):185–95.  https://doi.org/10.1016/j.otc.2017.09.005.CrossRefGoogle Scholar
  9. 9.
    Shirley MD, Tang H, Gallione CJ, et al. Sturge–weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med. 2013;368(21):1971–9.  https://doi.org/10.1056/NEJMoa1213507.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Comi AM. Sturge–Weber syndrome. Handb Clin Neurol. 2015;132:157–68.  https://doi.org/10.1016/B978-0-444-62702-5.00011-1.CrossRefPubMedGoogle Scholar
  11. 11.
    Wang SK, Drucker NA, Gupta AK, Marshalleck FE, Dalsing MC. Diagnosis and management of the venous malformations of Klippel-Trénaunay syndrome. J Vasc Surg Venous Lymphat Disord. 2017;5(4):587–95.  https://doi.org/10.1016/j.jvsv.2016.10.084.CrossRefPubMedGoogle Scholar
  12. 12.
    Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131(1):128–40.  https://doi.org/10.1542/peds.2012-1691.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Khan M, Boyce A, Prieto-Merino D, Svensson Å, Wedgeworth E, Flohr C. The role of topical timolol in the treatment of infantile hemangiomas: a systematic review and meta-analysis. Acta Derm Venereol. 2017;97(10):1167–71.  https://doi.org/10.2340/00015555-2681.CrossRefPubMedGoogle Scholar
  14. 14.
    Schwartz T, Faria J, Pawar S, Siegel D, Chun RH. Efficacy and rebound rates in propranolol-treated subglottic hemangioma: a literature review. Laryngoscope. 2017;127(11):2665–72.  https://doi.org/10.1002/lary.26818.CrossRefPubMedGoogle Scholar
  15. 15.
    Bhattacharyya N, Lin HW. Changes and consistencies in the epidemiology of pediatric adenotonsillar surgery, 1996–2006. Otolaryngol Head Neck Surg. 2010;143(5):680–4.  https://doi.org/10.1016/j.otohns.2010.06.918.CrossRefPubMedGoogle Scholar
  16. 16.
    Cho YK, Ryu DW, Chung HY, O TM, Blei F, Waner M. Surgical management of scalp infantile hemangiomas. J Craniofac Surg. 2015;26(4):1169–72.  https://doi.org/10.1097/SCS.0000000000001561.CrossRefPubMedGoogle Scholar
  17. 17.
    Rosenberg TL, Richter GT. Lasers in the treatment of vascular anomalies. Curr Otorhinolaryngol Rep. 2014;2(4):265–72.  https://doi.org/10.1007/s40136-014-0065-6.CrossRefGoogle Scholar
  18. 18.
    Ashinoff R, Geronemus RG. Flashlamp-pumped pulsed dye laser for port-wine stains in infancy: earlier versus later treatment. J Am Acad Dermatol. 1991;24(3):467–72.CrossRefGoogle Scholar
  19. 19.
    Bitar MA, Moukarbel RV, Zalzal GH. Management of congenital subglottic hemangioma: trends and success over the past 17 years. Otolaryngol Head Neck Surg. 2005;132(2):226–31.  https://doi.org/10.1016/j.otohns.2004.09.136.CrossRefPubMedGoogle Scholar
  20. 20.
    Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982;69(3):412–22.CrossRefGoogle Scholar
  21. 21.
    Mahajan P, Margolin J, Iacobas I. Kasabach-Merritt phenomenon: classic presentation and management options. Clin Med Insights Blood Disord. 2017;10:1179545X1769984.  https://doi.org/10.1177/1179545X17699849.CrossRefGoogle Scholar
  22. 22.
    Perkins JA, Manning SC, Tempero RM, et al. Lymphatic malformations: review of current treatment. Otolaryngol Neck Surg. 2010;142(6):795–803.e1.  https://doi.org/10.1016/j.otohns.2010.02.026.CrossRefGoogle Scholar
  23. 23.
    Groselj A, Krzan M, Kosjek T, Bosnjak M, Sersa G, Cemazar M. Bleomycin pharmacokinetics of bolus bleomycin dose in elderly cancer patients treated with electrochemotherapy. Cancer Chemother Pharmacol. 2016;77(5):939–47.  https://doi.org/10.1007/s00280-016-3004-z.CrossRefPubMedGoogle Scholar
  24. 24.
    Huang T-T, Hudson MM, Stokes DC, Krasin MJ, Spunt SL, Ness KK. Pulmonary outcomes in survivors of childhood cancer: a systematic review. Chest. 2011;140(4):881–901.  https://doi.org/10.1378/chest.10-2133.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Samuels ML, Johnson DE, Holoye PY, Lanzotti VJ. Large-dose bleomycin therapy and pulmonary toxicity. A possible role of prior radiotherapy. JAMA. 1976;235(11):1117–20.CrossRefGoogle Scholar
  26. 26.
    Mefferd JM, Donaldson SS, Link MP. Pediatric Hodgkin’s disease: pulmonary, cardiac, and thyroid function following combined modality therapy. Int J Radiat Oncol Biol Phys. 1989;16(3):679–85.CrossRefGoogle Scholar
  27. 27.
    Adams DM, Trenor CC, Hammill AM, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016;137(2):e20153257.  https://doi.org/10.1542/peds.2015-3257.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Huber S, Bruns CJ, Schmid G, et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int. 2007;71(8):771–7.  https://doi.org/10.1038/sj.ki.5002112.CrossRefPubMedGoogle Scholar
  29. 29.
    Moes DJAR, Guchelaar H-J, de Fijter JW. Sirolimus and everolimus in kidney transplantation. Drug Discov Today. 2015;20(10):1243–9.  https://doi.org/10.1016/j.drudis.2015.05.006.CrossRefPubMedGoogle Scholar
  30. 30.
    Mizuno T, Emoto C, Fukuda T, Hammill AM, Adams DM, Vinks AA. Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies. Eur J Pharm Sci. 2017;109:S124–31.  https://doi.org/10.1016/j.ejps.2017.05.037.CrossRefGoogle Scholar
  31. 31.
    Lipner SR. Topical adjuncts to pulsed dye laser for treatment of port wine stains. Dermatol Surg. 2018;44(6):796–802.  https://doi.org/10.1097/DSS.0000000000001507.CrossRefPubMedGoogle Scholar
  32. 32.
    Dompmartin A, Acher A, Thibon P, et al. Association of localized intravascular coagulopathy with venous malformations. Arch Dermatol. 2008;144(7):873–7.  https://doi.org/10.1001/archderm.144.7.873.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Eivazi B, Werner JA. Extracranial vascular malformations (hemangiomas and vascular malformations) in children and adolescents – diagnosis, clinic, and therapy. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2014;13:Doc02.  https://doi.org/10.3205/cto000105.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Cohen A, Dobromirski M. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism. Thromb Haemost. 2012;107(06):1035–43.  https://doi.org/10.1160/TH11-12-0859.CrossRefPubMedGoogle Scholar
  35. 35.
    Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014;13(2):140–56.  https://doi.org/10.1038/nrd4204.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Castel P, Carmona FJ, Grego-Bessa J, et al. Somatic PIK3CA mutations as a driver of sporadic venous malformations. Sci Transl Med. 2016;8(332):332ra42.  https://doi.org/10.1126/scitranslmed.aaf1164.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    ISSVA Classification for Vascular Anomalies ©.Google Scholar
  38. 38.
    Venot Q, Blanc T, Rabia SH, et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature. 2018;558(7711):540–6.  https://doi.org/10.1038/s41586-018-0217-9.CrossRefPubMedGoogle Scholar
  39. 39.
    Chewning RH, Monroe EJ, Lindberg A, et al. Combined glue embolization and excision for the treatment of venous malformations. CVIR Endovasc. 2018;1(1):22.  https://doi.org/10.1186/s42155-018-0028-y.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Austin N. DeHart
    • 1
    Email author
  • Joana M. Mack
    • 2
  • P. Spencer Lewis
    • 3
  • Shelley E. Crary
    • 2
  • Gresham T. Richter
    • 1
  1. 1.Department of Otolaryngology-Head and Neck Surgery, Division of Pediatric OtolaryngologyArkansas Children’s Hospital, University of Arkansas for Medical SciencesLittle RockUSA
  2. 2.Pediatric Hematology-OncologyUniversity of Arkansas for Medical Sciences, Arkansas Children’s HospitalLittle RockUSA
  3. 3.Pediatric Interventional RadiologyUniversity of Arkansas for Medical Sciences, Arkansas Children’s HospitalLittle RockUSA

Personalised recommendations